How should efficacy be evaluated in randomized clinical trials of treatments for depression?

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 4, 1999, Pages 23-32

  Thase, Michael E ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NORTRIPTYLINE; TRAZODONE;

BUDGET; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; DOSE CALCULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PATENT; PATIENT SELECTION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW;

DEPRESSIVE DISORDER; DRUG APPROVAL; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RESEARCH SUPPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0033057820     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Ma or Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
2. Thase ME, Kupfer DJ. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol 1996;64:646-659
3. McKinney WT. Animal research and its relevance to psychiatry. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. 6th ed. Baltimore, Md: Williams & Wilkins; 1995:400-404
4. Levine J. History and role of guidelines and guidance for drug evaluation. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:1-12
5. Lasagna L. Decision process in establishing the efficacy and safety of psychotropic agents. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:13-28
6. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992;81:605-610
7. New Drug Development in the United States. US Dept Health Human Services, Food and Drug Administration. Rockville, Md: HHS publication (FDA) 88-3168; 1976
8. Klerman GL, Weissman MM, Frank E, et al. Evaluating drug treatments of depressive disorders. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:281-325
9. Laughren TP, Levine J, Levine JG, et al. Premarketing safety evaluation of psychotropic drugs. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:185-215
10. Endicott J, Schwartz GE, Lee JH. Classification issues in patient selection and description. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:69-83
11. Merkatz RB, Temple R, Sobel S, et al. Women in clinical trials of new drugs. N Engl J Med 1993;329:292-296
12. Hollister LE, Jones JK, Fisher S. Post-marketing surveillance of drugs. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994:217-235
13. Klein DF. Clinical psychopharmacologic practice: the need for developing a research base. Arch Gen Psychiatry 1993;50:491-494
14. Thase ME, Rowland R. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 1994;24:232-240
15. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(6, suppl):60-69
16. Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Arch Gen Psychiatry 1996;53:913-919
17. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153:69-76
18. Stewart JW, Quitkin PJ, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55:334-343
19. Keller MB, Kocsis JH, Thase MR, et al, and the Sertraline Chronic Depression Study Group. Maintenance phase efficacy of sertraline for chronic depression: a double-blind, placebo-controlled study. JAMA. In press
20. Flament MF, Bisserbe J-C. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 1997;58(suppl 2): 18-22
21. Gorman JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry 1997;58(suppl 14):54-58
22. Keck PE Jr, McElroy SL. New uses for antidepressants: social phobia. J Clin Psychiatry 1997;58(suppl 14):32-36
23. Jimerson DC, Herzog DB, Brotman AW. Pharmacologic approaches in the treatment of eating disorders. Harv Rev Psychiatry 1993;1(2):82-93
24. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163(suppl 21):30-34
25. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
26. Trivedi MH, Rush J. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994;11:33-43
27. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851-855
28. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder. Arch Gen Psychiatry 1991;48:796-800
29. Riso LP, Thase ME, Howland RH, et al. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord 1997;43:131-142
30. Laska EM, Klein DF, Lavori PW, et al. Design issues for the clinical evaluation of psychotropic drugs. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs. New York, NY: Raven Press; 1994: 29-67
31. Eddy DM, Hasselblad V, Shacter R. An introduction to a Bayesian method for meta-analysis: the confidence profile method. Med Decis Making 1990;10:15-23
32. Moher D, Olkin I. Meta-analysis of randomized controlled trials: a concern for standards. JAMA 1995;274:1962-1964
33. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-1015
34. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59: 502-508